Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

Cited In for PubMed (Select 11348605)

1.

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.

Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2015 May 1;36(17):1012-22. doi: 10.1093/eurheartj/ehv043. Epub 2015 Feb 18. Review.

2.

Association between statin use and cancer: data mining of a spontaneous reporting database and a claims database.

Fujimoto M, Higuchi T, Hosomi K, Takada M.

Int J Med Sci. 2015 Jan 22;12(3):223-33. doi: 10.7150/ijms.10656. eCollection 2015.

3.

Facts and principles learned at the 39th Annual Williamsburg Conference on Heart Disease.

Benjamin MM, Roberts WC.

Proc (Bayl Univ Med Cent). 2013 Apr;26(2):124-36. No abstract available.

4.

Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications.

Karaca-Mandic P, Swenson T, Abraham JM, Kane RL.

Health Serv Res. 2013 Aug;48(4):1311-33. doi: 10.1111/1475-6773.12022. Epub 2012 Dec 26.

5.

How do we improve patient compliance and adherence to long-term statin therapy?

Maningat P, Gordon BR, Breslow JL.

Curr Atheroscler Rep. 2013 Jan;15(1):291. doi: 10.1007/s11883-012-0291-7. Review.

6.

Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk.

Conly J, Clement F, Tonelli M, Hemmelgarn B, Klarenbach S, Lloyd A, McAlister FA, Husereau D, Wiebe N, Au F, Manns B; Alberta Kidney Disease Network.

CMAJ. 2011 Nov 8;183(16):E1180-8. doi: 10.1503/cmaj.101281. Epub 2011 Oct 11.

7.

The complex interplay between cholesterol and prostate malignancy.

Solomon KR, Freeman MR.

Urol Clin North Am. 2011 Aug;38(3):243-59. doi: 10.1016/j.ucl.2011.04.001. Epub 2011 Jun 22. Review.

8.

Niacin or ezetimibe for patients with, or at risk of coronary heart disease.

Guthrie R.

Clin Med Insights Cardiol. 2010 Oct 31;4:99-110. doi: 10.4137/CMC.S5970.

9.

Combination therapy in cholesterol reduction: focus on ezetimibe and statins.

Grigore L, Norata GD, Catapano AL.

Vasc Health Risk Manag. 2008;4(2):267-78. Review.

10.

Elevated K-ras activity with cholestyramine and lovastatin, but not konjac mannan or niacin in lung--importance of mouse strain.

Calvert RJ, Tepper S, Kammouni W, Anderson LM, Kritchevsky D.

Biochem Pharmacol. 2006 Dec 15;72(12):1749-55. Epub 2006 Sep 3.

11.

Long-term statin use and psychological well-being.

Young-Xu Y, Chan KA, Liao JK, Ravid S, Blatt CM.

J Am Coll Cardiol. 2003 Aug 20;42(4):690-7.

12.

Problems in dealing with missing data and informative censoring in clinical trials.

Shih W.

Curr Control Trials Cardiovasc Med. 2002 Jan 8;3(1):4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk